What is the main business of Eirpharma?

The main business activity of Eirpharma focuses on manufacture of basic pharmaceutical products.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on January 3, 2020.

Where is the headquarters located?

The headquarters is located at: ul. Młyńska 12, 61-730 Poznań.

Who is on the management board?

The management board consists of: Farouk Hejazi (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What revenue was generated?

The company reported a revenue of $0 in 2024, which is a decrease of 98.9% compared to 2023.

No, in 2024 the company was not profitable, reporting a net loss of $3,030. For comparison, in 2023 the loss was $103,082, meaning the company reduced its loss by 97.2%.

What is the largest operating cost?

The largest operating cost category falls under other operating costs. This category amounted to $3,030 in 2024, representing 100% of all operating expenses.

Eirpharmasp. z o.o.

Manufacture of basic pharmaceutical products

KRS: NIP: REGON:

Overview

Status

Suspended

Registry date

2020-01-03

Share capital

5,000.00 PLN

Registered address

ul. Młyńska 12/215, 61-730 Poznań, Poland

Financials

Revenue history

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 4 of 5 financial statements were filed late (the longest delay 449 days for 2023).

2025not filed
202407/10/2025
202307/10/2025
202231/10/2023
202117/11/2022
202006/09/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue

This companyUSD 0.04MedianUSD 165.97kAverageUSD 2.30m

Net profit

This companyUSD -3.03kMedianUSD 1.32kAverageUSD 109.80k

Operating costs

This companyUSD 3.03kMedianUSD 201.81kAverageUSD 2.10m

Assets

This companyUSD 10.21kMedianUSD 118.27kAverageUSD 1.54m

Industry

Authorized Representatives

Farouk Hejazi – President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Eir Group Aps	100	$1,350.62	100%

Beneficial owners

Person	Rights

Bank accounts

Was a VAT taxpayer from 2020-01-18 to 2026-05-15.

Reason for removal: Art. 96 ust. 9a pkt 1 (business activity suspended for at least 6 consecutive months)

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Delpharm PoznańS.A.	$110,900,246.81	delpharm.com
Poznańskie Zakłady Zielarskie HerbapolS.A.	$31,668,225.77	herbapol.poznan.pl
Przedsiębiorstwo Farmaceutyczne Farmapolsp. z o.o.	$21,462,728.43	farmapol.pl
Przedsiębiorstwo Produkcyjno-Handlowe EwaS.A.	$14,322,437.53	ewa-sa.pl
Natur DayS.A.	$680,635.59	naturday.pl
Biotriosp. z o.o.	$453,662.22	biotrio.pl
Nature's Voicesp. z o.o.	$181,977.76	naturesvoice.eu
Pexon Polandsp. z o.o.	$122,615.96	pexon.pl
Bioresearch PharmaS.A.	$21,432.15	bioresearchpharma.com
Grupa FinepharmS.A.	–	finepharm.pl

Change history

Date	Event
2025-10-13	Business suspended
2024-01-22	Address change (Ul. Młyńska 12/107, 61-730, Poznań → Ul. Młyńska 12/215, 61-730, Poznań)
2021-07-30	Name change (Mktplace → Eirpharma)
2021-07-30	PKD change (Removed: 7 codes; Added: 7 codes)
2020-12-18	Address change (Ul. Młyńska 12/314, 61-730, Poznań → Ul. Młyńska 12/107, 61-730, Poznań)

FAQ

Last updated: 2026-10-07